The Motley Fool··Justin PopeDanaher Stock Plunges 36% but Masimo Deal Signals Recovery Ahead
Danaher trades 31% below historical valuation after 36% decline, but Masimo acquisition and resumed growth suggest recovery is underway for the storied life sciences leader.
DHRMASIacquisitionfree cash flow